Please login to the form below
Cosentyx
This page shows the latest Cosentyx news and features for those working in and with pharma, biotech and healthcare.
Novartis stumbles in Q2 as COVID-19 impacts sales
Its psoriasis and arthritis drug Cosentyx (secukinumab) also saw a sales rise of 12% to $944m, while its heart failure drug Entresto (sacubitril/valsartan) climbed 40% to $508m. ... Our growth drivers and launches continue their strong momentum, with
Latest news
-
Skyrizi, Rinvoq help AbbVie weather Humira slowdown
The growth came despite another strong quarter for Novartis’ IL-17 inhibitor Cosentyx (secukinumab) in psoriasis – currently leading the charge among a new generation of biologic therapies for the skin disorder
-
Cosentyx, Entresto drive topline growth for Novartis in Q4
Cosentyx was Novartis’ top-seller, bringing in $3.6bn in Q4, a 28% growth from the third quarter, where Novartis posted sales of $937m. ... Following Cosentyx was Entresto, which grew by 71% in Q4 to $1.7bn, an impressive increase from the $430m
-
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx
Skyrizi also met a non-inferiority endpoint at 16 weeks, with 74% of patients achieving PASI 90 versus 66% for Cosentyx. ... It is administered every six weeks, while Cosentyx is given once a month.
-
J&J splashes $750m on anti-inflammatory drug bermekimab
As well as facing competition from Cosentyx and Skyrizi, Tremfya also has to contend with Eli Lilly’s IL-17 inhibitor Taltz (ixekizumab) and Pfizer’s oral JAK inhibitor Xeljanz (tofacitinib),
-
UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial
If it can prove superiority over Cosentyx, UCB may have the upper hand, as well as determining whether IL-17F activity has any significant effect on patient outcomes.
More from news
Approximately 31 fully matching, plus 65 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
Hudson had a distinguished career at Novartis, presiding over the launches and roll-outs of psoriasis blockbuster Cosentyx (secukinumab), spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec) and heart failure therapy
-
Pharma: in search of the sustainable ‘win win’ with the NHS
An Outcomes Guarantee model - Cosentyx promise. Among the many initiatives Novartis is working on with the NHS is ‘The Cosentyx Promise’. ... Cosentyx is the company's psoriasis treatment, and Novartis supplies the drug with an outcomes guarantee.
-
Can value-based healthcare take off and reach for the skies?
costs. It was then backed with a ‘no response-no payment’ contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.
-
The good, the bad and the ugly
Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic arthritis treatment - Cosentyx - while GSK’s lupus therapy, Benlysta, has helped it increase immunology revenues by almost 45%.”.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Maker Projects
Our clients include: The NHS NWEH Cancer Research Cosentyx / Novartis Brilinta / AstraZeneca Port of Call We have branches in Manchester and London - to find out more: www.makerprojects.co.
-
90TEN nominated for five Communiqué Awards
Year. 90TEN’s work with Novartis on the global launch of Cosentyx is nominated for Excellence in Media Relations.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
- Roche’s Ocrevus boasts positive long-term data in MS
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
